Related Experiment Video
Updated: Sep 27, 2025
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
Published on: September 1, 2023
The Potential of Circulating Cell-Free DNA Methylation as an Epilepsy Biomarker
Ricardo Martins-Ferreira1,2,3,4, Bárbara Guerra Leal2,3,4, Paulo Pinho Costa2,3,4,5
1Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain.
Abstract:
Circulating cell-free DNA (cfDNA) are highly degraded DNA fragments shed into the bloodstream. Apoptosis is likely to be the main source of cfDNA due to the matching sizes of cfDNA and apoptotic DNA cleavage fragments. The study of cfDNA in liquid biopsies has served clinical research greatly. Genetic analysis of these circulating fragments has been used in non-invasive prenatal testing, detection of graft rejection in organ transplants, and cancer detection and monitoring. cfDNA sequencing is, however, of limited value in settings in which genetic association is not well-established, such as most neurodegenerative diseases.Recent studies have taken advantage of the cell-type specificity of DNA methylation to determine the tissue of origin, thus detecting ongoing cell death taking place in specific body compartments. Such an approach is yet to be developed in the context of epilepsy research. In this article, we review the different approaches that have been used to monitor cell-type specific death through DNA methylation analysis, and recent data detecting neuronal death in neuropathological settings. We focus on the potential relevance of these tools in focal epilepsies, like Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS), characterized by severe neuronal loss. We speculate on the potential relevance of cfDNA methylation screening for the detection of neuronal cell death in individuals with high risk of epileptogenesis that would benefit from early diagnosis and consequent early treatment.
Insights
Circulating cell-free DNA (cfDNA) methylation analysis shows promise for detecting neuronal death, particularly in Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS). This approach could enable early diagnosis and treatment for individuals at risk of epileptogenesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Circulating cell-free DNA (cfDNA) are DNA fragments in the bloodstream, primarily from apoptosis.
- cfDNA analysis is valuable in prenatal testing, transplant monitoring, and cancer detection.
- Genetic analysis of cfDNA has limitations in neurodegenerative diseases due to poorly established genetic links.
Purpose of the Study:
- To review methods for monitoring cell-type specific death using DNA methylation analysis.
- To explore the potential of cfDNA methylation in epilepsy research, specifically for detecting neuronal death.
- To assess the relevance of these tools for Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS).
Main Methods:
- Review of existing literature on DNA methylation analysis for cell-type specific death detection.
- Examination of recent data on neuronal death detection in neuropathological conditions.
- Focus on the application of cfDNA methylation in epilepsy, particularly MTLE-HS.
Main Results:
- DNA methylation patterns can identify the tissue of origin of cfDNA, indicating cell death in specific compartments.
- Recent studies have demonstrated the detection of neuronal death using these methylation-based approaches.
- The potential for cfDNA methylation screening in epilepsy, especially MTLE-HS, is highlighted.
Conclusions:
- cfDNA methylation analysis offers a novel approach to detect cell-type specific death.
- This method holds significant potential for diagnosing and monitoring neurological conditions like epilepsy.
- Early detection of neuronal death via cfDNA methylation could lead to timely interventions for epileptogenesis.
